In cerebral palsy, the term cerebral refers to brain and palsy refers to the loss or impairment of motor function. Cerebral palsy is a group of neurological disorders that appear in infancy or early childhood, and permanently affect body movement and muscle coordination. It is caused by damage or abnormalities inside the developing brain that disrupt its ability to control movement and maintain posture and balance. Cerebral palsy affects the motor area of the brain’s outer layer (called the cerebral cortex), that directs muscle movement. In some cases, the cerebral motor cortex is not developed normally during fetal growth. In other case the damage is a result of injury to the brain either before, during, or after birth. In either case, the damage is not repairable and the disabilities that result are permanent. Children with cerebral palsy exhibit a wide variety of symptoms like lack of muscle coordination when performing voluntary movements (ataxia), stiff or tight muscles and exaggerated reflexes (spasticity), weakness in one or more arm or leg, walking on the toes, and a crouched gait. Some drug candidates of cerebral palsy pipeline include, but are not limited to, Incobotulinumtoxin A and botulinum toxin type A.
-
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
-
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
